Alcobra Ltd. (NASDAQ:ADHD)’s share price rose 3.1% during trading on Tuesday . The stock traded as high as $4.32 and last traded at $4.29, with a volume of 54,177 shares changing hands. The stock had previously closed at $4.16.

ADHD has been the subject of several research analyst reports. Zacks Investment Research raised shares of Alcobra from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, April 28th. Canaccord Genuity began coverage on shares of Alcobra in a research report on Tuesday, June 7th. They set a “buy” rating for the company. Roth Capital reissued a “buy” rating and set a $12.00 price target on shares of Alcobra in a research report on Tuesday, June 21st. Finally, Cantor Fitzgerald began coverage on shares of Alcobra in a research report on Tuesday, June 7th. They set a “buy” rating and a $16.00 price target for the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $10.63.

The firm’s 50-day moving average is $4.49 and its 200-day moving average is $4.59. The stock’s market capitalization is $117.14 million.

Alcobra (NASDAQ:ADHD) last released its earnings results on Monday, May 16th. The company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.04. On average, equities research analysts anticipate that Alcobra Ltd. will post ($0.98) earnings per share for the current year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.